“Increased Adoption of Moxidectin”
The adoption of moxidectin is growing as it offers a longer-lasting effect compared to ivermectin, which means patients require fewer doses for effective treatment. This trend is leading to improved treatment adherence, as patients are more likely to complete their treatment regimens with less frequent dosing. The extended duration of moxidectin’s effect also contributes to enhanced overall treatment effectiveness, as it reduces the need for regular follow-ups and ensures more consistent results in controlling onchocerciasis.
Frequently Asked Questions
The market is segmented based on Segmentation, By Drug Type (Ivermectin, Doxycycline, Albendazole, and Moxidectin), Mode of Administration (Oral, Injectables, and Topical), Treatment Strategy (Mass Drug Administration (MDA) and Targeted Treatment), End-User (Hospitals & Clinics, Home Care Settings, and Government & Non-Governmental Programs), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Industry Trends and Forecast to 2032
.
The Global Onchocerciasis Treatment Market size was valued at USD 589.52 USD Million in 2024.
The Global Onchocerciasis Treatment Market is projected to grow at a CAGR of 8.78% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.
